VMAT2 Inhibitor Heterocyclic Compound and Preparation Method

The USPTO published a patent application (US20260091029A1) for heterocyclic compounds that function as VMAT2 inhibitors, including the compound represented by formula (I) and its stereoisomers or pharmaceutically acceptable salts. The application covers the preparation method and use of these compounds in preparing medicaments for treating diseases or disorders related to VMAT2 and Sigma-1 receptor. The filing date was December 9, 2025, with Application No. 19414124.

Patent applicants and pharmaceutical researchers developing VMAT2-targeted therapies should review this publication to assess potential prior art implications for their own filings or R&D programs. While this document represents informational publication of a patent application rather than an issued patent or regulatory requirement, it establishes a priority date for the disclosed compounds and methods. Companies engaged in similar research should evaluate freedom-to-operate considerations.